Medical use of cannabis for dry eye disease

(November 2018)

Background

The clinical value of cannabis in alleviating the symptoms of dry eye disease (DED) is limited at this time due to a lack of clinical evidence.

The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of DED or its associated pain symptoms, due to its undesirable side-effects, including dry eye symptoms if smoked, and the absence of scientific evidence showing any beneficial effect at this time.

Other evidence-based, less harmful treatment modalities are available for DED and its associated symptoms.

Access Details

Read the full position statement and recommendations from the Canadian Ophthalmological Society (COS).

Related Resources

Recommendations from the Canadian Neuro-Ophthalmology Society regarding Neuro-Ophthalmology Care During the COVID-19 Pandemic

May 29, 2020 As we transition into a new normal...

More Info

COS – Ophthalmic Surgery Prioritization

Ophthalmic Surgery Prioritization Updated, May 28, 2020 Hospitals and ambulatory...

More Info

Checklist on Reopening Ophthalmology Clinics during COVID-19

Checklist on Reopening Ophthalmology Clinics during COVID-19 May 15, 2020...

More Info

Please join us tomorrow Thursday May 28th at 7pm EST for the final webinar in our series - A Path to a New Vision: What Now? Optimizing Our New Normal #stayathome4CPD #COVID19 #eyehealth ow.ly/fTAC50zRsb4

Last week from Can Ophthal Society's Twitter via Hootsuite Inc.

Can Ophthal Society's Twitter via Twitter Web Client